sirolimus and Spinal-Cord-Neoplasms

Brain subependymal giant cell astrocytomas (SEGAs) in patients with tuberous sclerosis have been reported to respond to everolimus.. A 15-year-old male patient with intractable seizures and multiple SEGAs of the brain developed leptomeningeal enhancement and multiple metastatic, histologically confirmed SEGAs of the spinal cord. He received daily everolimus at a dose of 3 mg/m for 6 weeks, which was then increased to 6 mg/m.. Magnetic resonance image of the brain and spine showed significant reduction in the size of SEGAs after 6 weeks of treatment. The patient has remained free of progression for 24 months. Additional benefits included: excellent seizure control, decrease in the size of cardiac rhabdomyomas, and improved quality of life.. We describe a rare case of metastatic SEGA, which was successfully treated with everolimus.

Topics: Adolescent; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Everolimus; Humans; Male; Sirolimus; Spinal Cord Neoplasms; Treatment Outcome; Tuberous Sclerosis